466 related articles for article (PubMed ID: 31998289)
1. Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies.
Melamed E; Lee MW
Front Immunol; 2019; 10():2954. PubMed ID: 31998289
[TBL] [Abstract][Full Text] [Related]
2. Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients.
Chouhfeh L; Kavak KS; Teter BE; Weinstock-Guttman B
Mult Scler Relat Disord; 2015 May; 4(3):228-33. PubMed ID: 26008939
[TBL] [Abstract][Full Text] [Related]
3. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.
Konen FF; Möhn N; Witte T; Schefzyk M; Wiestler M; Lovric S; Hufendiek K; Schwenkenbecher P; Sühs KW; Friese MA; Klotz L; Pul R; Pawlitzki M; Hagin D; Kleinschnitz C; Meuth SG; Skripuletz T
Autoimmun Rev; 2023 May; 22(5):103312. PubMed ID: 36924922
[TBL] [Abstract][Full Text] [Related]
4. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Rae-Grant A; Day GS; Marrie RA; Rabinstein A; Cree BAC; Gronseth GS; Haboubi M; Halper J; Hosey JP; Jones DE; Lisak R; Pelletier D; Potrebic S; Sitcov C; Sommers R; Stachowiak J; Getchius TSD; Merillat SA; Pringsheim T
Neurology; 2018 Apr; 90(17):777-788. PubMed ID: 29686116
[TBL] [Abstract][Full Text] [Related]
5. microRNAs: key modulators of disease-modifying therapies in multiple sclerosis.
Ehtesham N; Mosallaei M; Karimzadeh MR; Moradikazerouni H; Sharifi M
Int Rev Immunol; 2020; 39(6):264-279. PubMed ID: 32552273
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
7. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
[TBL] [Abstract][Full Text] [Related]
8. Cancer and multiple sclerosis in the era of disease-modifying treatments.
Lebrun C; Vermersch P; Brassat D; Defer G; Rumbach L; Clavelou P; Debouverie M; de Seze J; Wiertlevsky S; Heinzlef O; Tourbah A; Fromont A; Frenay M
J Neurol; 2011 Jul; 258(7):1304-11. PubMed ID: 21293872
[TBL] [Abstract][Full Text] [Related]
9. The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists.
Edinger A; Habibi M
Am J Health Syst Pharm; 2024 Jan; 81(2):37-55. PubMed ID: 37777869
[TBL] [Abstract][Full Text] [Related]
10. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy.
Nakahara J; Maeda M; Aiso S; Suzuki N
Clin Rev Allergy Immunol; 2012 Feb; 42(1):26-34. PubMed ID: 22189514
[TBL] [Abstract][Full Text] [Related]
11. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
Gaindh D; Kavak KS; Teter B; Vaughn CB; Cookfair D; Hahn T; Weinstock-Guttman B;
J Neurol Sci; 2016 Nov; 370():13-17. PubMed ID: 27772741
[TBL] [Abstract][Full Text] [Related]
12. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
13. Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice.
Happe LE
Am J Manag Care; 2013 Nov; 19(17 Suppl):s332-42. PubMed ID: 24494634
[TBL] [Abstract][Full Text] [Related]
14. Classifying PML risk with disease modifying therapies.
Berger JR
Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic decisions in multiple sclerosis: moving beyond efficacy.
Brück W; Gold R; Lund BT; Oreja-Guevara C; Prat A; Spencer CM; Steinman L; Tintoré M; Vollmer TL; Weber MS; Weiner LP; Ziemssen T; Zamvil SS
JAMA Neurol; 2013 Oct; 70(10):1315-24. PubMed ID: 23921521
[TBL] [Abstract][Full Text] [Related]
16. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.
Karussis D; Petrou P
Immunol Res; 2018 Dec; 66(6):642-648. PubMed ID: 30443887
[TBL] [Abstract][Full Text] [Related]
17. Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs' Access in Multiple Sclerosis.
Shao H; Stoecker C; Monnette AM; Shi L
Value Health; 2018 Sep; 21(9):1083-1089. PubMed ID: 30224113
[TBL] [Abstract][Full Text] [Related]
18. Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives.
Bhise V; Dhib-Jalbut S
Neurotherapeutics; 2021 Jan; 18(1):244-251. PubMed ID: 33533012
[TBL] [Abstract][Full Text] [Related]
19. Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.
Schweitzer F; Laurent S; Fink GR; Barnett MH; Hartung HP; Warnke C
J Neurol; 2021 Jul; 268(7):2379-2389. PubMed ID: 32036423
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of disease-modifying therapies in multiple sclerosis.
Manouchehrinia A; Constantinescu CS
Curr Neurol Neurosci Rep; 2012 Oct; 12(5):592-600. PubMed ID: 22782520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
